Free Trial
→ $2 Trillion Disappears Because of Fed's Secretive New Move (From Stansberry Research) (Ad) Buy AGIO Stock  Free AGIO Stock Alerts

Agios Pharmaceuticals (AGIO) Financials

Agios Pharmaceuticals logo
$27.82 +0.30 (+1.09%)
Closing price 04:00 PM Eastern
Extended Trading
$27.82 0.00 (-0.02%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Agios Pharmaceuticals

Annual Income Statements for Agios Pharmaceuticals

This table shows Agios Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -54 -118 -198 -315 -346 -411 -327 1,605 -232 -352 674
Consolidated Net Income / (Loss)		 -54 -118 -198 -315 -346 -411 -327 1,605 -232 -352 674
Net Income / (Loss) Continuing Operations		 -54 -118 -198 -315 -346 -301 -329 -357 -232 -352 680
Total Pre-Tax Income 		-54 -118 -198 -315 -346 -301 -329 -357 -232 -352 718
Total Operating Income		 -54 -119 -201 -321 -362 -316 -336 -378 -389 -391 -426
Total Gross Profit		 65 59 70 43 93 0.00 0.00 0.00 13 24 32
Total Revenue		 65 59 70 43 94 0.00 0.00 0.00 14 27 36
Operating Revenue		 65 59 70 43 94 - - 0.00 14 27 36
Total Cost of Revenue		 0.00 0.00 0.00 0.00 1.40 0.00 0.00 0.00 1.70 2.88 4.17
Operating Cost of Revenue		 - - 0.00 0.00 1.40 - - 0.00 1.70 2.88 4.17
Total Operating Expenses		 119 178 271 364 455 316 336 378 402 415 458
Selling, General & Admin Expense		 19 36 51 71 114 102 115 121 122 120 157
Research & Development Expense		 100 142 220 293 341 214 221 257 280 296 301
Total Other Income / (Expense), net		 0.20 0.97 2.51 6.12 16 15 6.61 22 157 39 1,137
Interest & Investment Income		 0.20 0.97 2.51 6.12 16 15 6.61 7.48 23 33 48
Other Income / (Expense), net		 - - - - - - 0.00 14 135 6.06 1,089
Income Tax Expense		 -0.43 - - - - - - - 0.00 0.00 44
Other Gains / (Losses), net		 - - - - - 0.00 - - - - 6.49
Basic Earnings per Share		 ($1.59) ($3.15) ($5.07) ($6.75) ($6.03) ($6.86) ($4.74) $26.55 ($4.23) ($6.33) $11.86
Weighted Average Basic Shares Outstanding		 33.67M 37.43M 39.13M 46.59M 57.42M 59.99M 69.00M 60.45M 54.79M 55.65M 56.81M
Diluted Earnings per Share		 ($1.59) ($3.15) ($5.07) ($6.75) ($6.03) ($6.86) ($4.74) $26.55 ($4.23) ($6.33) $11.64
Weighted Average Diluted Shares Outstanding		 33.67M 37.43M 39.13M 46.59M 57.42M 59.99M 69.00M 60.45M 54.79M 55.65M 57.89M
Weighted Average Basic & Diluted Shares Outstanding		 33.67M 37.43M 39.13M 46.59M 57.42M 59.99M 69.00M 54.64M 55.29M 56.19M 57.30M

Quarterly Income Statements for Agios Pharmaceuticals

This table shows Agios Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -82 37 -81 -84 -91 -96 -82 -96 948 -97
Consolidated Net Income / (Loss)		 -82 37 -81 -84 -91 -96 -82 -96 948 -97
Net Income / (Loss) Continuing Operations		 -82 37 -81 -84 -91 -96 -82 -96 950 -92
Total Pre-Tax Income 		-82 39 -81 -84 -91 -96 -83 -96 1,001 -104
Total Operating Income		 -91 -99 -91 -94 -101 -106 -92 -106 -103 -125
Total Gross Profit		 3.00 3.90 5.06 5.60 6.77 6.52 7.56 7.12 8.18 9.47
Total Revenue		 3.52 4.31 5.61 6.71 7.40 7.10 8.19 8.62 8.96 11
Operating Revenue		 3.52 4.31 5.61 6.71 7.40 7.10 8.19 8.62 8.96 11
Total Cost of Revenue		 0.52 0.41 0.55 1.11 0.63 0.59 0.63 1.50 0.78 1.26
Operating Cost of Revenue		 0.52 0.41 0.55 1.11 0.63 0.59 0.63 1.50 0.78 1.26
Total Operating Expenses		 94 103 96 99 108 113 100 113 111 135
Selling, General & Admin Expense		 29 33 28 30 26 35 31 36 39 52
Research & Development Expense		 65 70 67 69 82 77 69 77 72 83
Total Other Income / (Expense), net		 9.34 139 9.60 9.89 9.57 10 8.89 9.70 1,102 16
Interest & Investment Income		 8.26 6.49 8.09 8.25 8.38 8.62 8.89 8.12 13 18
Basic Earnings per Share		 ($1.49) $0.68 ($1.47) ($1.51) ($1.64) ($1.71) ($1.45) ($1.69) $16.65 ($1.65)
Weighted Average Basic Shares Outstanding		 54.84M 54.79M 55.27M 55.60M 55.80M 55.65M 56.38M 56.80M 56.94M 56.81M
Diluted Earnings per Share		 ($1.49) $0.68 ($1.47) ($1.51) ($1.64) ($1.71) ($1.45) ($1.69) $16.22 ($1.44)
Weighted Average Diluted Shares Outstanding		 54.84M 54.79M 55.27M 55.60M 55.80M 55.65M 56.38M 56.80M 58.43M 57.89M
Weighted Average Basic & Diluted Shares Outstanding		 54.94M 55.29M 55.58M 55.74M 55.89M 56.19M 56.77M 56.89M 57.03M 57.30M

Annual Cash Flow Statements for Agios Pharmaceuticals

This table details how cash moves in and out of Agios Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 -58 58 89 -58 -32 10 47 76 -64 -51 -12
Net Cash From Operating Activities		 -59 -77 39 -285 -304 -371 -291 -407 -309 -296 -390
Net Cash From Continuing Operating Activities		 -59 -77 39 -285 -304 -236 -244 -314 -309 -296 -390
Net Income / (Loss) Continuing Operations		 -54 -118 -198 -315 -346 -301 -329 -357 -232 -352 674
Consolidated Net Income / (Loss)		 -54 -118 -198 -315 -346 -411 -327 1,605 -232 -352 674
Depreciation Expense		 1.37 3.34 5.70 6.43 7.17 8.09 9.79 9.24 8.56 6.62 5.65
Amortization Expense		 0.54 0.54 0.77 -0.01 -3.84 -3.20 3.02 6.95 -1.20 -5.05 -14
Non-Cash Adjustments To Reconcile Net Income		 12 30 45 49 67 61 71 63 -69 60 -1,050
Changes in Operating Assets and Liabilities, net		 -19 6.64 185 -26 -28 -0.41 1.97 -37 -16 -5.39 -4.76
Net Cash From Investing Activities		 -333 128 -119 -58 -274 91 76 1,249 243 240 363
Net Cash From Continuing Investing Activities		 -333 128 -119 -58 -274 92 77 -554 243 240 363
Purchase of Property, Plant & Equipment		 -2.22 -20 -9.92 -4.63 -6.99 -12 -14 -5.74 -4.88 -1.00 -1.69
Purchase of Investments		 -837 -353 -506 -689 -933 -489 -557 -1,378 -1,031 -418 -1,542
Sale of Property, Plant & Equipment		 - - - - - - 0.00 0.00 0.96 1.33 0.04
Divestitures		 - - - - - - - - 0.00 0.00 200
Sale and/or Maturity of Investments		 506 502 397 635 666 592 648 830 1,146 675 818
Other Investing Activities, net		 0.57 - - - - - 0.00 0.00 132 -18 889
Net Cash From Financing Activities		 335 6.37 170 285 546 290 262 -766 2.35 5.43 14
Net Cash From Continuing Financing Activities		 335 6.37 170 285 546 290 11 -766 2.35 5.43 14
Issuance of Common Equity		 334 6.58 170 284 547 290 11 37 2.68 5.43 14
Other Financing Activities, net		 2.30 - - 0.64 0.00 -0.11 -0.34 -0.58 -0.33 0.00 0.00
Cash Income Taxes Paid		 5.98 - - - - 0.00 0.00 16 0.00 1.57 43

Quarterly Cash Flow Statements for Agios Pharmaceuticals

This table details how cash moves in and out of Agios Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 34 17 -35 -19 -20 24 31 -34 169 -177
Net Cash From Operating Activities		 -71 -66 -95 -67 -62 -72 -100 -73 -84 -133
Net Cash From Continuing Operating Activities		 -71 -66 -95 -67 -62 -72 -100 -73 -84 -133
Net Income / (Loss) Continuing Operations		 -82 37 -81 -84 -91 -96 -82 -96 948 -97
Consolidated Net Income / (Loss)		 -82 37 -81 -84 -91 -96 -82 -96 948 -97
Depreciation Expense		 1.98 1.81 1.79 1.81 1.62 1.40 1.35 1.59 1.35 1.37
Amortization Expense		 -0.66 -1.92 -2.78 -2.96 1.08 -0.39 -2.53 -2.61 -3.73 -5.62
Non-Cash Adjustments To Reconcile Net Income		 6.04 -106 9.28 18 20 13 8.20 18 -1,086 10
Changes in Operating Assets and Liabilities, net		 3.03 3.67 -22 0.50 7.46 9.10 -25 6.48 57 -42
Net Cash From Investing Activities		 104 83 58 47 39 96 125 37 251 -49
Net Cash From Continuing Investing Activities		 104 83 58 47 39 96 125 37 251 -49
Purchase of Property, Plant & Equipment		 -0.04 -0.11 -0.40 0.00 -0.37 -0.23 -0.14 -0.16 -0.42 -0.97
Purchase of Investments		 -174 -249 -128 -104 -95 -90 -244 -105 -996 -198
Sale and/or Maturity of Investments		 279 199 186 151 151 186 369 142 158 150
Other Investing Activities, net		 - 132 - - - - - - - -200
Net Cash From Financing Activities		 1.19 0.02 2.47 0.24 1.88 0.85 5.86 1.10 2.64 4.84
Net Cash From Continuing Financing Activities		 1.19 0.02 2.47 0.24 1.88 0.85 5.86 1.10 2.64 4.84
Issuance of Common Equity		 1.27 0.11 2.47 0.24 1.88 0.85 5.86 1.10 2.64 4.84
Cash Income Taxes Paid		 0.10 -1.94 0.00 0.80 0.79 -0.02 -0.53 -0.08 -0.03 44

Annual Balance Sheets for Agios Pharmaceuticals

This table presents Agios Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 492 420 619 614 858 891 853 1,438 1,239 937 1,663
Total Current Assets		 360 337 560 445 614 612 637 1,064 833 834 966
Cash & Equivalents		 14 72 161 103 71 81 127 203 139 88 76
Short-Term Investments		 328 245 381 321 515 484 445 817 644 689 817
Accounts Receivable		 8.83 12 3.43 0.00 5.08 8.95 0.00 4.38 2.21 2.81 4.11
Inventories, net		 - - - 0.00 0.87 7.33 - 0.00 8.49 19 28
Prepaid Expenses		 4.81 8.73 10 18 17 24 16 40 39 35 40
Plant, Property, & Equipment, net		 6.39 23 25 24 24 31 31 29 23 15 12
Total Noncurrent Assets		 126 60 34 145 220 248 185 345 383 88 686
Long-Term Investments		 125 59 32 144 220 153 98 266 314 29 638
Other Noncurrent Operating Assets		 0.59 0.61 1.62 0.89 0.24 94 85 78 69 58 48
Total Liabilities & Shareholders' Equity		 492 420 619 614 858 891 853 1,438 1,239 937 1,663
Total Liabilities		 68 75 261 239 171 250 453 146 138 126 122
Total Current Liabilities		 61 53 88 95 94 93 94 60 63 68 81
Accounts Payable		 11 15 17 23 18 22 18 17 19 9.78 17
Accrued Expenses		 14 16 32 34 42 53 31 32 30 43 47
Current Deferred & Payable Income Tax Liabilities		 - - - - - - - - - 0.00 0.87
Other Current Liabilities		 0.01 - - 38 33 6.92 7.41 11 14 15 17
Total Noncurrent Liabilities		 6.45 22 172 144 77 157 359 86 75 58 41
Other Noncurrent Operating Liabilities		 - - - 126 60 106 97 86 75 58 41
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 424 345 359 376 688 641 400 1,292 1,101 811 1,541
Total Preferred & Common Equity		 424 345 359 376 688 641 400 1,292 1,101 811 1,541
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Common Equity		 424 345 359 376 688 641 400 1,292 1,101 811 1,541
Common Stock		 591 630 842 1,175 1,794 2,156 2,243 2,334 2,386 2,437 2,494
Retained Earnings		 -167 -285 -483 -798 -1,105 -1,516 -1,843 -239 -471 -823 -149
Treasury Stock		 - - - - - - 0.00 -802 -802 -802 -802
Accumulated Other Comprehensive Income / (Loss)		 -0.06 -0.32 -0.31 -1.39 -2.17 0.20 0.11 -1.20 -13 -0.44 -1.52

Quarterly Balance Sheets for Agios Pharmaceuticals

This table presents Agios Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 1,180 1,151 1,085 1,007 850 773 1,792
Total Current Assets		 785 792 757 704 664 632 1,074
Cash & Equivalents		 122 104 85 64 119 85 254
Short-Term Investments		 605 635 618 583 479 485 751
Accounts Receivable		 5.59 1.78 2.25 1.18 3.45 3.76 3.12
Inventories, net		 5.18 11 16 17 23 24 26
Prepaid Expenses		 46 39 37 38 39 35 40
Plant, Property, & Equipment, net		 25 21 20 17 14 13 12
Total Noncurrent Assets		 370 338 308 286 172 128 706
Long-Term Investments		 298 272 244 225 116 75 656
Other Noncurrent Operating Assets		 72 66 64 61 56 53 50
Total Liabilities & Shareholders' Equity		 1,180 1,151 1,085 1,007 850 773 1,792
Total Liabilities		 130 115 121 120 106 113 165
Total Current Liabilities		 54 45 55 58 52 63 119
Accounts Payable		 10 8.66 12 13 11 10 17
Accrued Expenses		 30 22 29 30 25 37 33
Current Deferred & Payable Income Tax Liabilities		 - - - - - - 53
Other Current Liabilities		 13 14 14 15 15 16 16
Total Noncurrent Liabilities		 77 70 66 62 54 50 46
Other Noncurrent Operating Liabilities		 77 70 66 62 54 50 46
Total Equity & Noncontrolling Interests		 1,050 1,037 964 887 744 661 1,627
Total Preferred & Common Equity		 1,050 1,037 964 887 744 661 1,627
Preferred Stock		 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,050 1,037 964 887 744 661 1,627
Common Stock		 2,375 2,399 2,411 2,422 2,452 2,464 2,478
Retained Earnings		 -507 -552 -635 -727 -904 -1,000 -52
Treasury Stock		 -802 -802 -802 -802 -802 -802 -802
Accumulated Other Comprehensive Income / (Loss)		 -15 -8.41 -8.87 -5.90 -1.09 -1.05 3.42

Annual Metrics and Ratios for Agios Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Agios Pharmaceuticals' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 155.82% -9.55% 18.22% -38.46% 119.45% -100.00% 0.00% 0.00% 0.00% 88.36% 36.07%
EBITDA Growth		 -40.55% -119.84% -69.41% -61.62% -14.24% 13.30% -3.77% -7.64% 28.96% -55.36% 270.52%
EBIT Growth		 -39.22% -119.27% -69.32% -59.61% -12.99% 12.75% -6.21% -8.36% 30.09% -51.48% 272.12%
NOPAT Growth		 -39.22% -119.27% -69.32% -59.61% -12.99% 12.75% -6.21% -12.65% -2.81% -0.63% -45.78%
Net Income Growth		 -35.77% -120.04% -68.58% -58.55% -9.97% -18.91% 20.44% 590.18% -114.45% -51.89% 291.35%
EPS Growth		 43.82% -98.11% -60.95% -33.14% 10.67% -13.76% 30.90% 660.13% -115.93% -49.65% 283.89%
Operating Cash Flow Growth		 -5.24% -29.65% 150.11% -839.67% -6.73% -21.75% 21.55% -40.09% 24.02% 4.34% -31.68%
Free Cash Flow Firm Growth		 -18.23% -65.03% 145.60% -668.54% -32.68% 19.94% -10.52% -0.65% 7.49% -1.69% -46.89%
Invested Capital Growth		 31.60% 28.53% -598.21% 10.57% 38.68% 35.02% 72.01% 127.33% -34.77% 21.85% 91.69%
Revenue Q/Q Growth		 13.73% -12.46% 30.73% -23.00% 27.25% -100.00% 100.00% 0.00% 43.40% 11.62% 11.03%
EBITDA Q/Q Growth		 -38.58% -13.22% -8.85% -11.75% -2.05% 24.57% -36.80% -1.56% 35.56% 0.02% 259.44%
EBIT Q/Q Growth		 -36.53% -13.56% -8.95% -11.36% -1.75% 24.11% -36.30% -1.41% 35.53% -0.27% 263.01%
NOPAT Q/Q Growth		 -36.53% -13.56% -8.95% -11.36% -1.75% 24.11% -36.30% -5.43% 1.43% -1.85% 1.84%
Net Income Q/Q Growth		 -36.41% -13.45% -8.69% -11.24% -1.02% -2.63% 1.41% 0.19% 36.13% -60.32% -0.09%
EPS Q/Q Growth		 -174.65% -12.10% -5.41% -7.31% 3.83% -0.15% 3.66% 17.63% -80.77% -60.66% 2.37%
Operating Cash Flow Q/Q Growth		 8.96% -41.99% -34.92% -8.87% 0.09% -5.53% 13.20% -9.31% 5.48% -2.18% -18.43%
Free Cash Flow Firm Q/Q Growth		 0.00% -34.38% -27.13% -7.11% -1.54% 17.33% -1,177.58% 40.59% 10.46% -5.97% -12.61%
Invested Capital Q/Q Growth		 -42.95% 4.76% 2.79% -0.17% 0.26% 16.90% 91.14% 508.51% -84.17% -67.79% 126.27%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 98.52% 0.00% 0.00% 0.00% 88.03% 89.26% 88.59%
EBITDA Margin		 -79.91% -194.22% -278.30% -730.91% -380.50% 0.00% 0.00% 0.00% -1,735.11% -1,431.09% 1,793.43%
Operating Margin		 -82.83% -200.78% -287.57% -745.84% -384.03% 0.00% 0.00% 0.00% -2,732.07% -1,459.52% -1,166.47%
EBIT Margin		 -82.83% -200.78% -287.57% -745.84% -384.03% 0.00% 0.00% 0.00% -1,786.83% -1,436.95% 1,817.63%
Profit (Net Income) Margin		 -81.86% -199.14% -283.97% -731.60% -366.61% 0.00% 0.00% 0.00% -1,627.82% -1,312.63% 1,845.92%
Tax Burden Percent		 99.21% 100.00% 100.00% 100.00% 100.00% 136.52% 99.41% -450.12% 100.00% 100.00% 93.84%
Interest Burden Percent		 99.63% 99.18% 98.75% 98.09% 95.46% 95.30% 98.03% 97.95% 91.10% 91.35% 108.23%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.16%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,627.29% -6,465.52% -5,883.24%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,630.70% -6,457.32% -5,975.03%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5,607.92% 6,428.68% 5,940.53%
Return on Equity (ROE)		 -19.25% -30.60% -56.41% -85.73% -65.10% -61.97% -62.95% 189.74% -19.38% -36.83% 57.29%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,987.86% -5,585.20% -6,485.22% -5,946.11%
Operating Return on Assets (OROA)		 -15.62% -26.03% -38.68% -52.01% -49.22% 0.00% 0.00% 0.00% -19.01% -35.43% 51.02%
Return on Assets (ROA)		 -15.44% -25.82% -38.20% -51.02% -46.99% 0.00% 0.00% 0.00% -17.32% -32.36% 51.82%
Return on Common Equity (ROCE)		 -19.25% -30.60% -56.41% -85.73% -65.10% -61.97% -62.95% 189.74% -19.38% -36.83% 57.29%
Return on Equity Simple (ROE_SIMPLE)		 -12.61% -34.11% -55.35% -83.80% -50.33% -64.24% -81.94% 124.21% -21.06% -43.41% 43.72%
Net Operating Profit after Tax (NOPAT)		 -38 -83 -141 -225 -254 -221 -235 -265 -272 -274 -400
NOPAT Margin		 -57.98% -140.55% -201.30% -522.09% -268.82% 0.00% 0.00% 0.00% -1,912.45% -1,021.66% -1,094.58%
Net Nonoperating Expense Percent (NNEP)		 -4.72% -8.22% -12.17% -15.79% -13.44% -24.97% -16.21% 219.04% 3.40% -8.20% 91.79%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -24.74% -33.79% -25.93%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 1.48% 0.00% 0.00% 0.00% 11.97% 10.74% 11.41%
SG&A Expenses to Revenue		 29.25% 60.88% 72.56% 165.36% 120.93% 0.00% 0.00% 0.00% 854.45% 447.02% 429.57%
R&D to Revenue		 153.57% 239.90% 315.00% 680.48% 361.62% 0.00% 0.00% 0.00% 1,965.66% 1,101.76% 825.49%
Operating Expenses to Revenue		 182.83% 300.78% 387.57% 845.84% 482.55% 0.00% 0.00% 0.00% 2,820.11% 1,548.78% 1,255.06%
Earnings before Interest and Taxes (EBIT)		 -54 -119 -201 -321 -362 -316 -336 -364 -254 -385 663
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -52 -115 -195 -314 -359 -311 -323 -348 -247 -384 655
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 9.16 7.08 4.89 7.42 3.90 4.39 7.51 1.38 1.40 1.53 1.22
Price to Tangible Book Value (P/TBV)		 9.16 7.08 4.89 7.42 3.90 4.39 7.51 1.38 1.40 1.53 1.22
Price to Revenue (P/Rev)		 59.46 41.33 25.09 64.80 28.42 0.00 0.00 0.00 108.35 46.40 51.35
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.11 0.00 0.00 2.78
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 89.89% 0.00% 0.00% 35.95%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 85.18 116.69 94.14 38.32
Enterprise Value to Revenue (EV/Rev)		 52.30 34.98 16.88 51.60 19.89 0.00 0.00 0.00 31.31 16.34 9.37
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.52
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.52
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 30.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 27.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.19 -1.10 -1.35 -1.55 -1.29 -1.15 -1.09 -1.01 -1.00 -1.00 -0.99
Leverage Ratio		 1.25 1.19 1.48 1.68 1.39 1.32 1.68 1.35 1.12 1.14 1.11
Compound Leverage Factor		 1.24 1.18 1.46 1.65 1.32 1.26 1.64 1.33 1.02 1.04 1.20
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.11% 0.08% 0.02% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.11% 0.08% 0.02% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 99.90% 99.92% 99.98% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 2.30 2.07 3.70 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 3.24 2.85 4.86 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 34.54 18.63 2.90 4.21 7.06 3.89 0.41 7.12 6.26 4.35 11.05
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.89 6.38 6.33 4.69 6.56 6.59 6.74 17.79 13.30 12.27 11.90
Quick Ratio		 5.74 6.21 6.16 4.47 6.31 6.18 6.07 17.12 12.54 11.47 11.06
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -58 -95 43 -247 -328 -263 -290 -292 -270 -275 -404
Operating Cash Flow to CapEx		 -2,678.38% -381.62% 388.93% -6,164.51% -4,357.59% -3,081.33% -2,061.24% -7,094.93% -7,900.89% 0.00% -23,698.54%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.19 0.13 0.13 0.07 0.13 0.00 0.00 0.00 0.01 0.02 0.03
Accounts Receivable Turnover		 14.05 5.79 9.30 0.00 0.00 0.00 0.00 0.00 4.33 10.70 10.55
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.21 0.18
Fixed Asset Turnover		 12.89 3.99 2.88 1.73 3.87 0.00 0.00 0.00 0.55 1.40 2.70
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.07 0.00 0.00 0.00 0.10 0.20 0.32
Days Sales Outstanding (DSO)		 25.97 63.05 39.24 0.00 0.00 0.00 0.00 0.00 84.38 34.13 34.60
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,746.32 2,045.93
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 5,310.01 0.00 0.00 0.00 3,782.38 1,798.77 1,157.79
Cash Conversion Cycle (CCC)		 25.97 63.05 39.24 0.00 -5,310.01 0.00 0.00 0.00 -3,698.00 -18.32 922.73
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -43 -31 -215 -192 -118 -77 -21 5.86 3.82 4.66 8.93
Invested Capital Turnover		 -1.23 -1.60 -0.57 -0.21 -0.61 0.00 0.00 0.00 2.94 6.33 5.37
Increase / (Decrease) in Invested Capital		 20 12 -184 23 74 41 55 27 -2.04 0.84 4.27
Enterprise Value (EV)		 3,418 2,068 1,180 2,220 1,877 2,095 2,331 499 446 438 342
Market Capitalization		 3,886 2,444 1,753 2,787 2,683 2,812 3,001 1,785 1,543 1,245 1,874
Book Value per Share		 $12.24 $9.17 $8.53 $7.70 $11.82 $10.88 $5.77 $23.79 $20.03 $14.51 $27.02
Tangible Book Value per Share		 $12.24 $9.17 $8.53 $7.70 $11.82 $10.88 $5.77 $23.79 $20.03 $14.51 $27.02
Total Capital		 424 345 359 376 688 641 400 1,292 1,101 811 1,541
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.67 0.33 0.28 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.67 0.33 0.28 0.00 0.00 0.00
Net Debt		 -467 -376 -574 -568 -805 -717 -670 -1,286 -1,097 -806 -1,532
Capital Expenditures (CapEx)		 2.22 20 9.92 4.63 6.99 12 14 5.74 3.92 -0.33 1.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -44 -33 -70 -74 -65 -46 -31 -16 -13 -11 -9.27
Debt-free Net Working Capital (DFNWC)		 298 284 471 350 520 519 542 1,004 770 766 884
Net Working Capital (NWC)		 298 284 471 350 520 519 542 1,004 770 766 884
Net Nonoperating Expense (NNE)		 16 35 58 90 92 190 92 -1,870 -41 78 -1,073
Net Nonoperating Obligations (NNO)		 -467 -376 -574 -568 -805 -717 -421 -1,286 -1,097 -806 -1,532
Total Depreciation and Amortization (D&A)		 1.91 3.88 6.47 6.42 3.34 4.89 13 16 7.37 1.57 -8.83
Debt-free, Cash-free Net Working Capital to Revenue		 -66.72% -55.08% -99.95% -171.16% -68.89% 0.00% 0.00% 0.00% -91.12% -41.19% -25.39%
Debt-free Net Working Capital to Revenue		 456.65% 481.13% 674.55% 814.49% 551.22% 0.00% 0.00% 0.00% 5,408.31% 2,855.31% 2,423.27%
Net Working Capital to Revenue		 456.65% 481.13% 674.55% 814.49% 551.22% 0.00% 0.00% 0.00% 5,408.31% 2,855.31% 2,423.27%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.59) ($3.15) ($5.07) ($6.75) ($6.03) ($6.86) ($4.74) $26.55 ($4.23) ($6.33) $11.86
Adjusted Weighted Average Basic Shares Outstanding		 37.22M 37.85M 42.23M 57.33M 58.40M 68.51M 69.60M 60.45M 54.79M 55.65M 56.81M
Adjusted Diluted Earnings per Share		 ($1.59) ($3.15) ($5.07) ($6.75) ($6.03) ($6.86) ($4.74) $26.55 ($4.23) ($6.33) $11.64
Adjusted Weighted Average Diluted Shares Outstanding		 37.22M 37.85M 42.23M 57.33M 58.40M 68.51M 69.60M 60.45M 54.79M 55.65M 57.89M
Adjusted Basic & Diluted Earnings per Share		 ($1.59) ($3.15) ($5.07) ($6.75) ($6.03) ($6.86) ($4.74) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 33.67M 37.43M 39.13M 46.59M 57.42M 59.99M 69.00M 54.64M 55.29M 56.19M 57.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -38 -83 -141 -225 -254 -221 -235 -265 -272 -274 -400
Normalized NOPAT Margin		 -57.98% -140.55% -201.30% -522.09% -268.82% 0.00% 0.00% 0.00% -1,912.45% -1,021.66% -1,094.58%
Pre Tax Income Margin		 -82.51% -199.14% -283.97% -731.60% -366.61% 0.00% 0.00% 0.00% -1,627.82% -1,312.63% 1,967.15%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.18% 0.00% 0.00% 0.00% 0.00% 0.00% 50.01% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Agios Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Agios Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 574.16% 20.24% 110.44% 64.80% 46.00% 28.35% 21.15% 51.06%
EBITDA Growth		 -4.29% 1.71% 7.61% 0.60% -9.37% -4.31% -3.50% -12.92% 1,114.41% -24.85%
EBIT Growth		 -0.96% 5.39% 11.90% 4.41% -10.77% -5.44% -3.33% -13.23% 1,089.30% -19.58%
NOPAT Growth		 0.07% -35.15% 10.41% 4.04% -10.77% 24.99% -1.61% -12.93% -37.84% -17.65%
Net Income Growth		 7.91% 138.60% 14.51% 8.71% -11.72% -362.66% -0.66% -14.69% 1,137.97% -0.61%
EPS Growth		 4.49% -73.54% 15.52% 10.12% -10.07% -351.47% 1.36% -11.92% 1,089.02% 15.79%
Operating Cash Flow Growth		 16.24% 21.32% 2.61% 10.08% 13.61% -9.56% -4.92% -8.75% -36.62% -83.71%
Free Cash Flow Firm Growth		 70.65% 3.52% 62.02% 43.69% 31.78% 22.55% -12.89% -22.01% 19.71% -22.02%
Invested Capital Growth		 1,783.26% -34.77% -9.75% -27.61% -40.12% 21.85% 15.75% -12.12% -335.07% 91.69%
Revenue Q/Q Growth		 -37.01% 22.58% 30.14% 19.66% 10.24% -4.00% 15.29% 5.20% 4.05% 19.70%
EBITDA Q/Q Growth		 5.43% -11.94% 9.25% -3.46% -4.06% -6.76% 9.95% -12.87% 1,034.82% -113.14%
EBIT Q/Q Growth		 6.54% -10.18% 10.15% -3.31% -8.30% -4.88% 11.95% -13.21% 1,046.22% -112.68%
NOPAT Q/Q Growth		 6.71% -55.53% 36.04% -3.41% -7.68% -5.33% 13.37% -14.93% -31.43% 10.10%
Net Income Q/Q Growth		 10.96% 144.68% -321.81% -3.44% -8.97% -5.05% 15.00% -17.87% 1,086.20% -110.18%
EPS Q/Q Growth		 11.31% 145.64% -316.18% -2.72% -8.61% -4.27% 15.20% -16.55% 1,059.76% -108.88%
Operating Cash Flow Q/Q Growth		 3.88% 7.27% -43.86% 29.87% 7.65% -17.59% -37.77% 27.31% -16.02% -58.12%
Free Cash Flow Firm Q/Q Growth		 14.72% -8.73% 37.55% 2.76% -3.32% -23.44% 8.97% -5.10% 32.02% -87.61%
Invested Capital Q/Q Growth		 0.93% -84.17% 569.93% -32.37% -16.52% -67.79% 536.38% -48.65% -323.31% 126.27%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 85.30% 90.42% 90.12% 83.49% 91.44% 91.75% 92.34% 82.65% 91.27% 88.26%
EBITDA Margin		 -2,522.41% -2,303.41% -1,606.26% -1,388.78% -1,310.93% -1,457.89% -1,138.73% -1,221.75% 10,976.53% -1,204.90%
Operating Margin		 -2,590.73% -2,300.97% -1,615.49% -1,396.01% -1,363.66% -1,496.23% -1,124.34% -1,228.29% -1,146.93% -1,165.30%
EBIT Margin		 -2,559.95% -2,300.97% -1,588.68% -1,371.57% -1,347.47% -1,472.11% -1,124.34% -1,209.96% 11,003.18% -1,165.30%
Profit (Net Income) Margin		 -2,325.00% 847.47% -1,444.43% -1,248.60% -1,234.27% -1,350.70% -995.84% -1,115.71% 10,574.69% -899.56%
Tax Burden Percent		 100.00% 92.47% 100.00% 100.00% 100.00% 100.00% 98.04% 100.00% 94.69% 93.02%
Interest Burden Percent		 90.82% -39.83% 90.92% 91.03% 91.60% 91.75% 90.35% 92.21% 101.49% 82.99%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.31% 0.00%
Return on Invested Capital (ROIC)		 -1,586.34% -6,770.51% -797.05% -955.04% -1,188.78% -6,628.12% -838.03% -1,655.05% 0.00% -4,384.34%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,584.86% -6,781.90% -795.45% -953.26% -1,186.60% -6,625.86% -836.04% -1,652.28% 0.00% -4,383.57%
Return on Net Nonoperating Assets (RNNOA)		 1,570.14% 6,754.46% 776.32% 934.44% 1,162.96% 6,596.48% 810.11% 1,619.21% 0.00% 4,358.26%
Return on Equity (ROE)		 -16.20% -16.04% -20.73% -20.60% -25.82% -31.64% -27.92% -35.85% 53.65% -26.08%
Cash Return on Invested Capital (CROIC)		 -1,250.57% -5,585.20% -971.77% -1,239.90% -1,344.26% -6,485.22% -1,010.70% -1,730.53% 0.00% -5,946.11%
Operating Return on Assets (OROA)		 -18.68% -24.48% -24.29% -23.64% -29.60% -36.30% -33.04% -40.77% 258.43% -32.71%
Return on Assets (ROA)		 -16.96% 9.02% -22.09% -21.52% -27.12% -33.30% -29.27% -37.59% 248.37% -25.25%
Return on Common Equity (ROCE)		 -16.20% -16.04% -20.73% -20.60% -25.82% -31.64% -27.92% -35.85% 53.65% -26.08%
Return on Equity Simple (ROE_SIMPLE)		 -34.56% 0.00% -21.04% -21.78% -24.76% 0.00% -47.40% -55.25% 41.45% 0.00%
Net Operating Profit after Tax (NOPAT)		 -64 -99 -63 -66 -71 -74 -64 -74 -97 -88
NOPAT Margin		 -1,813.51% -2,300.97% -1,130.85% -977.21% -954.56% -1,047.36% -787.04% -859.80% -1,086.07% -815.71%
Net Nonoperating Expense Percent (NNEP)		 -1.48% 11.39% -1.61% -1.78% -2.18% -2.26% -1.98% -2.77% 82.53% -0.77%
Return On Investment Capital (ROIC_SIMPLE)		 - -9.01% - - - -9.17% - - - -5.68%
Cost of Revenue to Revenue		 14.70% 9.58% 9.88% 16.51% 8.56% 8.25% 7.66% 17.35% 8.73% 11.74%
SG&A Expenses to Revenue		 828.30% 760.35% 505.74% 453.05% 348.99% 497.04% 378.73% 412.49% 429.91% 481.80%
R&D to Revenue		 1,847.72% 1,631.04% 1,199.88% 1,026.45% 1,106.11% 1,090.93% 837.95% 898.44% 808.29% 771.76%
Operating Expenses to Revenue		 2,676.02% 2,391.39% 1,705.62% 1,479.50% 1,455.10% 1,587.98% 1,216.68% 1,310.93% 1,238.20% 1,253.56%
Earnings before Interest and Taxes (EBIT)		 -90 -99 -89 -92 -100 -105 -92 -104 986 -125
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -89 -99 -90 -93 -97 -104 -93 -105 984 -129
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.48 1.40 1.23 1.63 1.56 1.53 2.20 3.71 1.55 1.22
Price to Tangible Book Value (P/TBV)		 1.48 1.40 1.23 1.63 1.56 1.53 2.20 3.71 1.55 1.22
Price to Revenue (P/Rev)		 156.12 108.35 66.78 78.13 57.41 46.40 55.58 78.20 76.90 51.35
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.75 2.78
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.68% 35.95%
Enterprise Value to Invested Capital (EV/IC)		 21.72 116.69 10.12 36.22 35.09 94.14 31.05 118.49 0.00 38.32
Enterprise Value to Revenue (EV/Rev)		 52.79 31.31 13.62 31.13 21.11 16.34 31.29 57.58 26.38 9.37
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.52
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.52
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.99 -1.00 -0.98 -0.98 -0.98 -1.00 -0.97 -0.98 -1.01 -0.99
Leverage Ratio		 1.11 1.12 1.11 1.12 1.13 1.14 1.12 1.14 1.11 1.11
Compound Leverage Factor		 1.01 -0.45 1.01 1.02 1.03 1.04 1.02 1.05 1.13 0.92
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.99% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.05 6.67 6.51 7.51 6.33 5.33 8.32 11.72 11.62 9.48
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 14.65 13.30 17.55 13.73 12.06 12.27 12.84 10.09 8.99 11.90
Quick Ratio		 13.68 12.54 16.43 12.78 11.10 11.47 11.64 9.16 8.44 11.06
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -89 -97 -61 -59 -61 -75 -68 -72 -49 -92
Operating Cash Flow to CapEx		 -187,765.79% 0.00% -38,226.10% 0.00% 0.00% -30,977.78% -98,878.22% -45,942.41% -20,099.76% -13,771.15%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.02 0.02 0.02 0.02 0.03 0.03 0.02 0.03
Accounts Receivable Turnover		 1.58 4.33 4.95 6.15 7.10 10.70 11.24 10.41 15.31 10.55
Inventory Turnover		 0.00 0.00 0.28 0.26 0.24 0.21 0.17 0.17 0.16 0.18
Fixed Asset Turnover		 0.39 0.55 0.75 0.86 1.14 1.40 1.65 1.93 2.30 2.70
Accounts Payable Turnover		 0.12 0.10 0.19 0.27 0.23 0.20 0.30 0.31 0.23 0.32
Days Sales Outstanding (DSO)		 231.24 84.38 73.73 59.36 51.40 34.13 32.47 35.05 23.84 34.60
Days Inventory Outstanding (DIO)		 0.00 0.00 1,318.01 1,389.24 1,512.97 1,746.32 2,127.97 2,163.56 2,284.67 2,045.93
Days Payable Outstanding (DPO)		 2,929.47 3,782.38 1,922.29 1,367.06 1,596.27 1,798.77 1,224.31 1,183.22 1,589.96 1,157.79
Cash Conversion Cycle (CCC)		 -2,698.23 -3,698.00 -530.54 81.54 -31.90 -18.32 936.13 1,015.40 718.55 922.73
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 24 3.82 26 17 14 4.66 30 15 -34 8.93
Invested Capital Turnover		 0.87 2.94 0.70 0.98 1.25 6.33 1.06 1.92 -3.37 5.37
Increase / (Decrease) in Invested Capital		 26 -2.04 -2.77 -6.60 -9.69 0.84 4.03 -2.10 -48 4.27
Enterprise Value (EV)		 524 446 259 627 507 438 920 1,803 867 342
Market Capitalization		 1,550 1,543 1,270 1,574 1,380 1,245 1,634 2,448 2,528 1,874
Book Value per Share		 $19.16 $20.03 $18.75 $17.35 $15.91 $14.51 $13.19 $11.63 $28.59 $27.02
Tangible Book Value per Share		 $19.16 $20.03 $18.75 $17.35 $15.91 $14.51 $13.19 $11.63 $28.59 $27.02
Total Capital		 1,050 1,101 1,037 964 887 811 744 661 1,627 1,541
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,026 -1,097 -1,011 -947 -872 -806 -714 -645 -1,661 -1,532
Capital Expenditures (CapEx)		 0.04 -0.85 0.25 -0.00 -0.81 0.23 0.10 0.16 0.42 0.97
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 3.66 -13 7.34 -0.47 -1.56 -11 14 -0.40 -50 -9.27
Debt-free Net Working Capital (DFNWC)		 731 770 747 702 646 766 612 569 955 884
Net Working Capital (NWC)		 731 770 747 702 646 766 612 569 955 884
Net Nonoperating Expense (NNE)		 18 -136 18 18 21 22 17 22 -1,045 9.00
Net Nonoperating Obligations (NNO)		 -1,026 -1,097 -1,011 -947 -872 -806 -714 -645 -1,661 -1,532
Total Depreciation and Amortization (D&A)		 1.32 -0.11 -0.99 -1.16 2.70 1.01 -1.18 -1.02 -2.39 -4.25
Debt-free, Cash-free Net Working Capital to Revenue		 36.85% -91.12% 38.61% -2.32% -6.50% -41.19% 47.43% -1.28% -152.17% -25.39%
Debt-free Net Working Capital to Revenue		 7,364.94% 5,408.31% 3,925.66% 3,484.88% 2,688.00% 2,855.31% 2,081.20% 1,819.11% 2,904.50% 2,423.27%
Net Working Capital to Revenue		 7,364.94% 5,408.31% 3,925.66% 3,484.88% 2,688.00% 2,855.31% 2,081.20% 1,819.11% 2,904.50% 2,423.27%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.49) $0.68 ($1.47) ($1.51) ($1.64) ($1.71) ($1.45) ($1.69) $16.65 ($1.65)
Adjusted Weighted Average Basic Shares Outstanding		 54.84M 54.79M 55.27M 55.60M 55.80M 55.65M 56.38M 56.80M 56.94M 56.81M
Adjusted Diluted Earnings per Share		 ($1.49) $0.68 ($1.47) ($1.51) ($1.64) ($1.71) ($1.45) ($1.69) $16.22 ($1.44)
Adjusted Weighted Average Diluted Shares Outstanding		 54.84M 54.79M 55.27M 55.60M 55.80M 55.65M 56.38M 56.80M 58.43M 57.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.94M 55.29M 55.58M 55.74M 55.89M 56.19M 56.77M 56.89M 57.03M 57.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -64 -69 -63 -66 -71 -74 -64 -74 -97 -88
Normalized NOPAT Margin		 -1,813.51% -1,610.68% -1,130.85% -977.21% -954.56% -1,047.36% -787.04% -859.80% -1,086.07% -815.71%
Pre Tax Income Margin		 -2,325.00% 916.45% -1,444.43% -1,248.60% -1,234.27% -1,350.70% -1,015.79% -1,115.71% 11,167.28% -967.06%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Agios Pharmaceuticals' Financials

When does Agios Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Agios Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Agios Pharmaceuticals' net income changed over the last 10 years?

Agios Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $673.73 million in 2024, falling from -$53.50 million in 2014. The previous period was -$352.09 million in 2023.

What is Agios Pharmaceuticals's operating income?
Agios Pharmaceuticals's total operating income in 2024 was -$425.74 million, based on the following breakdown:
  • Total Gross Profit: $32.33 million
  • Total Operating Expenses: $458.07 million
How has Agios Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, Agios Pharmaceuticals' total revenue changed from $65.36 million in 2014 to $36.50 million in 2024, a change of -44.2%.

How much debt does Agios Pharmaceuticals have?

Agios Pharmaceuticals' total liabilities were at $122.24 million at the end of 2024, a 3.1% decrease from 2023, and a 81.0% increase since 2014.

How much cash does Agios Pharmaceuticals have?

In the past 10 years, Agios Pharmaceuticals' cash and equivalents has ranged from $14.03 million in 2014 to $203.13 million in 2021, and is currently $76.25 million as of their latest financial filing in 2024.

How has Agios Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Agios Pharmaceuticals' book value per share changed from 12.24 in 2014 to 27.02 in 2024, a change of 120.8%.

Remove Ads

Related Companies

This page (NASDAQ:AGIO) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...
InvestorPlace | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...
Altimetry | Sponsored
Amazon Shocker
Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...
Stansberry Research | Sponsored
Caught on Camera: Elon Musk’s “Area 51”
You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...
Brownstone Research | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored